Advances in Molecular Pathology, Diagnosis and Treatment of Spinal Cord Astrocytomas.
Zijun ZhaoZihan SongZairan WangFan ZhangZe DingTao FanPublished in: Technology in cancer research & treatment (2024)
Spinal cord astrocytoma (SCA) is a rare subtype of astrocytoma, posing challenges in diagnosis and treatment. Low-grade SCA can achieve long-term survival solely through surgery, while high-grade has a disappointing prognosis even with comprehensive treatment. Diagnostic criteria and standard treatment of intracranial astrocytoma have shown obvious limitations in SCA. Research on the molecular mechanism in SCA is lagging far behind that on intracranial astrocytoma. In recent years, huge breakthroughs have been made in molecular pathology of astrocytoma, and novel techniques have emerged, including DNA methylation analysis and radiomics. These advances are now making it possible to provide a precise diagnosis and develop corresponding treatment strategies in SCA. Our aim is to review the current status of diagnosis and treatment of SCA, and summarize the latest research advancement, including tumor subtype, molecular characteristics, diagnostic technology, and potential therapy strategies, thus deepening our understanding of this uncommon tumor type and providing guidance for accurate diagnosis and treatment.
Keyphrases
- low grade
- high grade
- spinal cord
- dna methylation
- current status
- minimally invasive
- neuropathic pain
- squamous cell carcinoma
- computed tomography
- genome wide
- single molecule
- magnetic resonance
- stem cells
- mass spectrometry
- risk assessment
- percutaneous coronary intervention
- bone marrow
- lymph node metastasis
- acute coronary syndrome
- atrial fibrillation
- contrast enhanced